Literature DB >> 23044489

Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives.

Frederic Dorandeu1, Laure Barbier, Franck Dhote, Guy Testylier, Pierre Carpentier.   

Abstract

Organophosphorus nerve agents (NA), potent irreversible cholinesterase inhibitors, could induce severe seizures, status epilepticus (SE), seizure-related brain damage (SRBD) and lethality. Despite the lack of data in the case of NA, clinical evidences suggest that SE survivors could suffer from neurological/cognitive deficits and impairments such as spontaneous recurrent seizures (epilepsy) after a latent period of epileptogenesis. It is beyond doubt that an effective and quick management of the initial seizures and prevention of SRBD are critical to prevent these long-term consequences, explaining why most experimental data are focusing on the 5-40min post-exposure time frame. However, in field conditions, treatment may be delayed and with the exception of NMDA receptor antagonists, currently no drug provides protection (against lethality, seizures, SRBD and neurological consequences) when seizures are left unabated for one hour or more. Ketamine (KET) is the only NMDA antagonist licensed as an injectable drug in different countries and remains an anesthetic of choice in some difficult field conditions. In this short review paper, after a presentation of some of the key points of the pathophysiology of NA-induced SE and a quick survey of the potential therapeutic avenues in the context of delayed treatment of NA-induced SE, we will review the recent data we obtained showing that KET, in combination with atropine sulfate (AS), with or without a benzodiazepine, considerably reduces soman-induced neuroinflammation, provides neuroprotection, histologically and functionally, and also positively modify soman-induced changes in brain metabolism. Finally, we will also mention some results from safety studies including those bringing evidence that, at difference with MK-801, KET does not impair thermoregulation and even seems to reduce AS-induced heat stress. All in all, KET, in combination, appears a good candidate for the out-of-hospital treatment of severe NA-induced SE.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23044489     DOI: 10.1016/j.cbi.2012.09.013

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  9 in total

Review 1.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

2.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 3.  Glutamatergic Mechanisms Associated with Seizures and Epilepsy.

Authors:  Melissa Barker-Haliski; H Steve White
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-22       Impact factor: 6.915

4.  Ketamine as adjunct to midazolam treatment following soman-induced status epilepticus reduces seizure severity, epileptogenesis, and brain pathology in plasma carboxylesterase knockout mice.

Authors:  Brenda M Marrero-Rosado; Marcio de Araujo Furtado; Erica R Kundrick; Katie A Walker; Michael F Stone; Caroline R Schultz; Donna A Nguyen; Lucille A Lumley
Journal:  Epilepsy Behav       Date:  2020-06-20       Impact factor: 2.937

Review 5.  Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development.

Authors:  Jennifer Leigh Green; Wagner Ferreira Dos Santos; Andréia Cristina Karklin Fontana
Journal:  Biochem Pharmacol       Date:  2021-09-24       Impact factor: 5.858

6.  Long-term administration of ketamine induces erectile dysfunction by decreasing neuronal nitric oxide synthase on cavernous nerve and increasing corporal smooth muscle cell apoptosis in rats.

Authors:  Hung-Sheng Shang; Yi-No Wu; Chun-Hou Liao; Tzong-Shi Chiueh; Yuh-Feng Lin; Han-Sun Chiang
Journal:  Oncotarget       Date:  2016-07-20

7.  Combination of antiseizure medications phenobarbital, ketamine, and midazolam reduces soman-induced epileptogenesis and brain pathology in rats.

Authors:  Lucille A Lumley; Brenda Marrero-Rosado; Franco Rossetti; Caroline R Schultz; Michael F Stone; Jerome Niquet; Claude G Wasterlain
Journal:  Epilepsia Open       Date:  2021-10-23

8.  Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats.

Authors:  Ashish Dhir; Donald A Bruun; Michelle Guignet; Yi-Hua Tsai; Eduardo González; Jonas Calsbeek; Joan Vu; Naomi Saito; Daniel J Tancredi; Danielle J Harvey; Pamela J Lein; Michael A Rogawski
Journal:  Ann N Y Acad Sci       Date:  2020-09-11       Impact factor: 5.691

Review 9.  Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy.

Authors:  Roberta Celli; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.